BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.

BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.

The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC). However, not all HCC patients respond to sorafenib well and...

Full description

Bibliographic Details
Main Authors: Wei-Chien Huang, Yi-Ling Hsieh, Chao-Ming Hung, Pei-Hsuan Chien, Yu-Fong Chien, Lei-Chin Chen, Chih-Yen Tu, Chia-Hung Chen, Sheng-Chieh Hsu, Yueh-Ming Lin, Yun-Ju Chen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3877048?pdf=render

Internet

http://europepmc.org/articles/PMC3877048?pdf=render

Similar Items